A promising cancer treatment has reached a remarkable new milestone.
Chimeric Antigen Receptor (CAR) T-cell therapy has already shown encouraging results against certain blood cancers, including some forms of leukemia and lymphoma. But using the therapy successfully against solid tumors has proved far more challenging — until now.
In a striking case, a 3-year-old boy with chemotherapy-resistant cancer that had spread from his liver to his lungs, with possible involvement of his bones, was declared cancer-free after receiving just two doses of an experimental CAR T-cell treatment.
CAR T-cell therapy has shown promising results against blood cancers, but its success in treating solid tumors has been far more limited — until now.
Researchers from Texas Children’s Hospital, Baylor College of Medicine and Seattle Children’s have reported striking progress involving an experimental CAR T-cell treatment. Their findings were published this month in the New England Journal of Medicine.
The case involved a 3-year-old boy diagnosed with hepatoblastoma, a form of liver cancer that primarily affects young children. He had developed a massive tumor measuring 4.4 × 3.8 × 2.8 inches.
Despite undergoing multiple rounds of chemotherapy and surgery to remove the tumor, the cancer returned. It spread to his lungs, and doctors also found evidence suggesting it may have reached his bones.
With conventional treatments failing to stop the disease, doctors turned to an experimental form of CAR T-cell therapy.
The treatment involves collecting a patient’s T cells — a type of white blood cell that plays a key role in the immune system — and genetically engineering them to recognize and attack cancer cells.
In this case, researchers used an experimental therapy known as GPC3-CAR T-cell therapy, designed to target glypican-3 (GPC3), a protein found at high levels on certain tumor cells, including hepatoblastoma.
The boy received two doses of the experimental treatment over an eight-week period. Following treatment, doctors could no longer detect signs of the cancer. One year later, he remained free of detectable disease, indicating a complete response.
“This study provides evidence that these novel CAR T cells may be a safe and effective modality for hepatoblastoma and highlights the need for further assessment in patients with GPC3+ solid tumors,” study co-author and pediatric oncologist Andras Heczey said.
The case is particularly significant because CAR T-cell therapies have transformed treatment for some blood cancers but have struggled to achieve the same success against solid tumors.
Liver cancer remains a major global health burden and is the third-leading cause of cancer-related deaths worldwide. For children with hepatoblastoma, treatment commonly involves chemotherapy and surgery, but the disease can be especially difficult to treat when it returns or spreads.
While the result involves a single patient and further research is needed to determine the treatment’s safety and effectiveness in larger groups, the case offers encouraging evidence that CAR T-cell therapy could eventually provide another option for children with difficult-to-treat solid tumors.
A hepatoblastoma tumor in a 3-year-old boy dramatically regressed following treatment with an experimental CAR T-cell therapy, according to the 2026 report by Steffin et al. in the New England Journal of Medicine.
Although CAR T-cell therapy has emerged as an innovative form of cancer immunotherapy, it is currently FDA-approved only for certain blood cancers, including specific leukemias, lymphomas and multiple myeloma.
Extending that success to solid tumors has proved much more difficult.
One major obstacle is the tumor microenvironment — the complex network of cells, molecules and other substances surrounding a tumor. This environment can suppress or destroy immune cells before they can effectively attack the cancer.
Solid tumors can also be difficult for engineered T cells to distinguish from healthy tissue. Cancer cells can exploit nearby healthy cells, including fibroblasts and regulatory immune cells, to create additional physical and biological barriers that help tumors evade an immune response.
The hepatoblastoma case adds to growing research into whether engineered T-cell therapies can overcome these defenses. It follows other encouraging studies investigating T-cell therapies for aggressive pediatric brain tumors.
Still, the liver cancer result involved just one patient in an early-phase clinical trial. Larger studies and longer follow-up will be needed to determine whether the treatment is consistently safe and effective for children with hepatoblastoma and other solid tumors.
Research into the GPC3-targeting CAR T-cell treatment is continuing through the CARE study at Baylor College of Medicine, an early clinical trial investigating the experimental therapy in pediatric patients with recurrent solid tumors.
While much remains to be established, the case provides encouraging evidence that CAR T-cell therapy may eventually have applications beyond the blood cancers for which the approach is currently approved.
